Last reviewed · How we verify
Tritanrix-HepB/Hib™ + OPV vaccine — Competitive Intelligence Brief
phase 3
vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Tritanrix-HepB/Hib™ + OPV vaccine (Tritanrix-HepB/Hib™ + OPV vaccine) — Sanofi Pasteur, a Sanofi Company. Tritanrix-HepB/Hib™ + OPV vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tritanrix-HepB/Hib™ + OPV vaccine TARGET | Tritanrix-HepB/Hib™ + OPV vaccine | Sanofi Pasteur, a Sanofi Company | phase 3 | vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Sabin IPV | Sabin IPV | Centers for Disease Control and Prevention, China | marketed | inactivated viral vaccine | poliovirus serotypes 1, 2, and 3 | |
| Healive+Healive | Healive+Healive | Sinovac Biotech Co., Ltd | marketed | Combination vaccine | Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg) | |
| Meningococcal A (control) | Meningococcal A (control) | International Vaccine Institute | marketed | polysaccharide vaccine | Neisseria meningitidis serogroup A capsular polysaccharide | |
| Intranasal Influenza Live Attenuated Vaccine | Intranasal Influenza Live Attenuated Vaccine | Jiangsu Province Centers for Disease Control and Prevention | marketed | Live attenuated influenza vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (vaccine class)
- Pfizer · 20 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
- GlaxoSmithKline · 12 drugs in this class
- Merck Sharp & Dohme LLC · 12 drugs in this class
- Centers for Disease Control and Prevention · 9 drugs in this class
- Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
- Beijing Center for Disease Control and Prevention · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
- Sinovac Biotech Co., Ltd · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tritanrix-HepB/Hib™ + OPV vaccine CI watch — RSS
- Tritanrix-HepB/Hib™ + OPV vaccine CI watch — Atom
- Tritanrix-HepB/Hib™ + OPV vaccine CI watch — JSON
- Tritanrix-HepB/Hib™ + OPV vaccine alone — RSS
- Whole vaccine class — RSS
Cite this brief
Drug Landscape (2026). Tritanrix-HepB/Hib™ + OPV vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/tritanrix-hepb-hib-opv-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab